Izvorni znanstveni članak
The Safety Profiles of Adalimumab, Infliximab, Etaner- cept, Secukinumab and Ustekinumab in Psoriasis – A 30-month Observational Cohort Prospective Study of Adverse Events in Biologic Therapy
Zoltán Paluch
; Department of Clinical Pharmacology and Pharmacy, General University Hospital, Prague, Czech Republic;
Emanuel Marques
; Department of Dermatology, and Venereology, Královské Vinohrady University Hospital, Prague, Czech Republic;
Petr Boháč
; Department of Dermatology, and Venereology, Bulovka University Hospital, Prague, Czech Republic;
Kateřina Zemková
; Department of Dermatology, and Venereology, Third Faculty of Medicine, Charles University, Prague, Czech Republic;
*
Jana Hercogová
; Dermatologie Prof. Hercogové, Prague, Czech Republic
* Dopisni autor.
Sažetak
Background: Although biologic agents are very effective, long-term comparative studies
demonstrating their safety relative to one another are still lacking.
Methods: A total of 124 patients with psoriasis were followed up for 30 months; 74 received
anti-TNF-alpha inhibitors (adalimumab, etanercept, infliximab), 33 were on ustekinumab,
and 17 were treated with secukinumab. The rates of adverse events in these groups were
recorded and statistically analyzed.
Results: Infliximab-treated patients showed a high occurrence of asymptomatic, but in-
creased liver enzymes, fatigue, and respiratory as well as dermatologic infections. Adalim-
umab-treated patients were more often affected by musculoskeletal disorders and infec-
tions of all types. Patients treated with secukinumab presented with higher rates of cardio-
vascular disorders as well as respiratory and dermatologic infections. The group receiving
etanercept was more often diagnosed with musculoskeletal and reproductive disorders,
specifically menstrual disorders. The rates of therapy discontinuation and serious adverse
events did not reach statistically significant values.
Conclusion: A higher incidence of adverse events was observed among adalimumab-,
and infliximab-treated patients, with ustekinumab found to have the safest profile. Our
results demonstrate that a personalized approach, including evaluation of a patient’s risk
profile, is necessary before commencing a biologic. Further research is warranted to con-
firm the findings of our study.
Ključne riječi
psoriasis; biologic agents; safety of biologic agents; adverse events caused by biologic agents
Hrčak ID:
335575
URI
Datum izdavanja:
1.2.2024.
Posjeta: 444 *